CTBP1 and polyposis: We have developed a novel class of anti-CtBP therapeutics based on 2-hydroxy-imino phenylpyruvate (HIPP), a CtBP dehydrogenase substrate competitive inhibitor12, and HIPP and higher-potency derivatives (4-Cl-HIPP)12, exhibit on-target inhibition of CtBP and phenocopy Ctbp2 haploinsufficiency in reducing polyposis in the Min mouse8.